BioNTech SE (VIE:BNTX)

Market Cap	22.78B +11.5%
Revenue (ttm)	2.87B +4.3%
Net Income	-1.14B
EPS	-4.70
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	279
Average Volume	359
Open	89.70
Previous Close	89.65
Day's Range	87.50 - 90.80
52-Week Range	68.65 - 110.40
Beta	n/a
RSI	59.99
Earnings Date	May 5, 2026

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 7,807
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: BNTX

Financial Performance

In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.